Assertio Therapeutics Inc (ASRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has a cash flow conversion efficiency ratio of 0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.56 Million) by net assets ($75.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ASRT net asset quality index to measure how much of total assets are equity-financed.
Assertio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ASRT cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Assertio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assertio Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jarllytec Co Ltd
TWO:3548
|
0.017x |
|
Orogen Royalties Inc
V:OGN
|
-0.027x |
|
AMA Group Ltd
AU:AMA
|
0.125x |
|
Fursys
KO:016800
|
0.002x |
|
Theta Gold Mines Ltd
AU:TGM
|
-0.181x |
|
Leclanche SA
SW:LECN
|
0.518x |
|
Gala Precision Engineering
NSE:GALAPREC
|
0.027x |
|
USBC, Inc.
NYSE MKT:USBC
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see ASRT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.95 Million | $-28.18 Million | -0.300x | -237.53% |
| 2024-12-31 | $121.08 Million | $26.41 Million | 0.218x | -39.32% |
| 2023-12-31 | $138.00 Million | $49.60 Million | 0.359x | +3.23% |
| 2022-12-31 | $225.72 Million | $78.60 Million | 0.348x | +545.68% |
| 2021-12-31 | $102.41 Million | $5.52 Million | 0.054x | +104.57% |
| 2020-12-31 | $55.51 Million | $-65.57 Million | -1.181x | -175.67% |
| 2019-12-31 | $57.96 Million | $90.47 Million | 1.561x | +374.44% |
| 2018-12-31 | $220.34 Million | $72.50 Million | 0.329x | -10.28% |
| 2017-12-31 | $169.51 Million | $62.17 Million | 0.367x | +40.42% |
| 2016-12-31 | $250.79 Million | $65.50 Million | 0.261x | -42.81% |
| 2015-12-31 | $315.06 Million | $143.89 Million | 0.457x | +397.67% |
| 2014-12-31 | $364.45 Million | $-55.92 Million | -0.153x | -316.15% |
| 2013-12-31 | $137.42 Million | $9.75 Million | 0.071x | +119.23% |
| 2012-12-31 | $83.94 Million | $-30.98 Million | -0.369x | -167.82% |
| 2011-12-31 | $105.92 Million | $57.65 Million | 0.544x | +628.20% |
| 2010-12-31 | $23.11 Million | $-2.38 Million | -0.103x | -188.17% |
| 2009-12-31 | $15.73 Million | $1.84 Million | 0.117x | +15.63% |
| 2008-12-31 | $33.15 Million | $3.35 Million | 0.101x | -68.62% |
| 2007-12-31 | $45.52 Million | $14.66 Million | 0.322x | -68.27% |
| 2006-12-31 | $-27.29 Million | $-27.70 Million | 1.015x | -76.18% |
| 2005-12-31 | $6.76 Million | $28.82 Million | 4.262x | +253.93% |
| 2004-12-31 | $8.40 Million | $-23.27 Million | -2.769x | -188.82% |
| 2003-12-31 | $34.58 Million | $-33.15 Million | -0.959x | -238.57% |
| 2002-12-31 | $-6.41 Million | $-4.44 Million | 0.692x | -91.76% |
| 2001-12-31 | $-1.48 Million | $-12.40 Million | 8.393x | +678.64% |
| 2000-12-31 | $4.59 Million | $-6.65 Million | -1.451x | -238.96% |
| 1999-12-31 | $9.22 Million | $-3.94 Million | -0.428x | -57.48% |
| 1998-12-31 | $9.20 Million | $-2.50 Million | -0.272x | -1.28% |
| 1997-12-31 | $4.10 Million | $-1.10 Million | -0.268x | -126.83% |
| 1996-12-31 | $-400.00K | $-400.00K | 1.000x | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more